Cengiz Taşçı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cengiz Taşçı has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Dirican
Medicana International Izmir
1 shared publication Coskun Ak
Ozel Gama Tip Tani Merkezi, Nukleer Tip Bolumu, Gaziantep, Turkey
1 shared publication- Elif Özdemir
Department of Nuclear Medicine, Ankara City Hospital, Ankara, Turkey
1 shared publication - Ethem Murat Sözbilen
Izmir Univ Econ, Med Point Hosp, Dept Gen Surg, Fac Med, I?zmir, Turkiye
1 shared publication - Fatma Seher Pehlivan
Department of Pathology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey
1 shared publication - Fevziye Canbaz Tosun
Ondokuz Mayıs University, Turkey
1 shared publication
Latest Publications
- Open Access
- 23 February 2024
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 33 (1) , 66-67
About the Article Titled “A Different Scintigraphic Perspective on the Systolic Function of the Left Ventricle-1”
- 23 February 2024
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 33 (1) , 66-67
Open AccessAbout the Article Titled “A Different Scintigraphic Perspective on the Systolic Function of the Left Ventricle-1”
- Open Access
- 1 June 2023
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 32 (2) , 181-185
Hypermetabolic Axillary Lymph Nodes Associated with COVID-19 Vaccination in Breast Cancer Management
A 42-year-old female patient diagnosed with invasive ductal breast ca underwent 18F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) scan for staging, 1.5 cm diameter hypermetabolic lesion was observed in the lower inner quadrant of the right breast that was compatible with primary tumor [maximum standardized uptake value (SUVmax): 10.5]. No pathological 18F-FDG uptake was observed in lymph nodes whose fatty hilum was seen in the right axilla. However, in the left axilla and left deep axilla, hypermetabolic lymph nodes with a maksimum diameter of 19 mm and fatty hilum were observed (SUVmax: 8.0). In a detailed CT evaluation, these lymph nodes have thicker walls than the ones in the right axilla. The patient was questioned again and coronavirus disease-2019 (COVID-19) vaccination history (with BNT162b2, COVID-19 mRNA vaccine) was determined that was administrated to the left arm 5 days ago. Tru-cut biopsy was performed from the left aksillary lymph nodes and proved to be reactive lymphoid tissue and there was no primary or metastatic tumor in these axillary lymph node tissues. The patient was given neoadjuvant chemotherapy 4.5 months after the first 18F-FDG PET/CT, and the second was performed for the treatment response evaluation. Significant regression was determined from the findings. The patient underwent right total mastechtomy. She was being followed up with adjuvant chemotherapy and radiotherapy. In conclusion, hypermetabolic lymph nodes in the axillas should be interrogated for vaccination in patients with breast cancer. Hypermetabolic lymph nodes observed on the same side of the vaccinated arm in the 18F-FDG PET/CT scan may be related to vaccine-induced reactive lymph node enlargement. Lymph node metastasis may be excluded, especially if there are hypermetabolic lymph nodes with preserved fatty hilum in the contralateral axilla on the same side as the vaccinated arm. Active lymph nodes reactive to the vaccine become inactive after a while.
- 1 June 2023
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 32 (2) , 181-185
Open AccessHypermetabolic Axillary Lymph Nodes Associated with COVID-19 Vaccination in Breast Cancer Management
A 42-year-old female patient diagnosed with invasive ductal breast ca underwent 18F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) scan for staging, 1.5 cm diameter hypermetabolic lesion was observed in the lower inner quadrant of the right breast that was compatible with primary tumor [maximum standardized uptake value (SUVmax): 10.5]. No pathological 18F-FDG uptake was observed in lymph nodes whose fatty hilum was seen in the right axilla. However, in the left axilla and left deep axilla, hypermetabolic lymph nodes with a maksimum diameter of 19 mm and fatty hilum were observed (SUVmax: 8.0). In a detailed CT evaluation, these lymph nodes have thicker walls than the ones in the right axilla. The patient was questioned again and coronavirus disease-2019 (COVID-19) vaccination history (with BNT162b2, COVID-19 mRNA vaccine) was determined that was administrated to the left arm 5 days ago. Tru-cut biopsy was performed from the left aksillary lymph nodes and proved to be reactive lymphoid tissue and there was no primary or metastatic tumor in these axillary lymph node tissues. The patient was given neoadjuvant chemotherapy 4.5 months after the first 18F-FDG PET/CT, and the second was performed for the treatment response evaluation. Significant regression was determined from the findings. The patient underwent right total mastechtomy. She was being followed up with adjuvant chemotherapy and radiotherapy. In conclusion, hypermetabolic lymph nodes in the axillas should be interrogated for vaccination in patients with breast cancer. Hypermetabolic lymph nodes observed on the same side of the vaccinated arm in the 18F-FDG PET/CT scan may be related to vaccine-induced reactive lymph node enlargement. Lymph node metastasis may be excluded, especially if there are hypermetabolic lymph nodes with preserved fatty hilum in the contralateral axilla on the same side as the vaccinated arm. Active lymph nodes reactive to the vaccine become inactive after a while.
- 26 August 2020
- Published by Galenos Yayinevi in Nuclear Medicine Seminars
- Vol. 6 (2) , 135-170
Standardized Reporting of Myocardial Perfusion SPECT Imaging
- 26 August 2020
- Published by Galenos Yayinevi in Nuclear Medicine Seminars
- Vol. 6 (2) , 135-170
Standardized Reporting of Myocardial Perfusion SPECT Imaging
- 2 September 2014
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 15 (3) , 145-153
Cost-effectiveness of Diagnostic Strategies in Guidance of Treatment Strategies in Stable Coronary Artery Disease: “Myocardial Perfusion Scan as a Gatekeeper”
- 2 September 2014
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 15 (3) , 145-153
Cost-effectiveness of Diagnostic Strategies in Guidance of Treatment Strategies in Stable Coronary Artery Disease: “Myocardial Perfusion Scan as a Gatekeeper”
- Open Access
- 5 April 2013
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 22 (1) , 21-22
The Evaluation Criteria in Diagnosing Ischemia with Stress and Rest Myocardial Perfusion Gated SPECT
- 5 April 2013
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 22 (1) , 21-22
Open AccessThe Evaluation Criteria in Diagnosing Ischemia with Stress and Rest Myocardial Perfusion Gated SPECT
- Open Access
- 15 December 2011
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 20 (3) , 75-93
An Overview on Coronary Heart Disease (A Comparative Evaluation of Turkey and Europe) and Cost-effectiveness of Diagnostic Strategies
Coronary heart disease (CHD) is the leading cause of death for men and women in Turkey as it is in Europe and US. The prevalence of the disease is 3.8% in Turkey and 200,000 patients are added to the pool of CHD annually Because of genetic predisposition and high proportions of physical inactivity, smoking habit, and obesity, CHD is encountered in earlier ages in our country So, the economic burden of the disease is expected to be relatively high, but the amount of health expenditure is not always parallel to the prevalence of a disease in the community. This article was written to overview CHD statistics to make a comparison between Turkey and some European countries and to investigate the value of myocardial perfusion scan (MPS) as a gatekeeper in diagnosing CHD before invasive coronary angiography (ICA). The consequences were evaluated for Turkey In diagnosis; noninvasive testing gains importance in connection with the new approaches in treatment strategies, because a direct ICA strategy results in higher rates of revascularization without improvement in clinical outcomes. A "gatekeeper" is needed to select the patients who are not required to undergo angiography. MPS with its proved power in diagnosis and predicting prognosis, provides a cost-effective solution, and is accepted in some extensive analyses as a "gatekeeper" particularly in intermediate and high risk patients and in patients with known CHD. In conclusion, MPS may provide an optimal solution better than the ongoing situation in Turkey as well, when it is approved as a "gatekeeper in an algorithm before ICA. None declared.
- 15 December 2011
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 20 (3) , 75-93
Open AccessAn Overview on Coronary Heart Disease (A Comparative Evaluation of Turkey and Europe) and Cost-effectiveness of Diagnostic Strategies
Coronary heart disease (CHD) is the leading cause of death for men and women in Turkey as it is in Europe and US. The prevalence of the disease is 3.8% in Turkey and 200,000 patients are added to the pool of CHD annually Because of genetic predisposition and high proportions of physical inactivity, smoking habit, and obesity, CHD is encountered in earlier ages in our country So, the economic burden of the disease is expected to be relatively high, but the amount of health expenditure is not always parallel to the prevalence of a disease in the community. This article was written to overview CHD statistics to make a comparison between Turkey and some European countries and to investigate the value of myocardial perfusion scan (MPS) as a gatekeeper in diagnosing CHD before invasive coronary angiography (ICA). The consequences were evaluated for Turkey In diagnosis; noninvasive testing gains importance in connection with the new approaches in treatment strategies, because a direct ICA strategy results in higher rates of revascularization without improvement in clinical outcomes. A "gatekeeper" is needed to select the patients who are not required to undergo angiography. MPS with its proved power in diagnosis and predicting prognosis, provides a cost-effective solution, and is accepted in some extensive analyses as a "gatekeeper" particularly in intermediate and high risk patients and in patients with known CHD. In conclusion, MPS may provide an optimal solution better than the ongoing situation in Turkey as well, when it is approved as a "gatekeeper in an algorithm before ICA. None declared.